CB2810 has been market-specific as an antidepressant and has been clinically safe for more than 25 years. We are repurposing CB2810 in a new indication and to protect its use and formulation through a new patent filing. The drug has potential to be useful in insomnia, specifically in patients suffering from CNS disorders by enhancing sleep latency and duration. Morning drowsiness and hang-over are not expected. We will be confirming the repurposed indication in a proof-of-concept trial in humans.